Evaluating Lip Repositioning for the Treatment of Excess Gingival Display with and without Pretreatment with Botox: A Randomized Clinical Trial.
TL;DR
Botox pre-injection for LRS demonstrated its efficacy for management of EGD by enhancing lip length, reducing relapse, alleviating postoperative discomfort, and providing sustained results for 1 year, according to a Randomized Clinical Trial.
OpenAlex 토픽 ·
Orthodontics and Dentofacial Orthopedics
Botulinum Toxin and Related Neurological Disorders
Temporomandibular Joint Disorders
Botox pre-injection for LRS demonstrated its efficacy for management of EGD by enhancing lip length, reducing relapse, alleviating postoperative discomfort, and providing sustained results for 1 year,
APA
Ola M Ghoniem, Gehan G Madkor, Mona Darhous (2025). Evaluating Lip Repositioning for the Treatment of Excess Gingival Display with and without Pretreatment with Botox: A Randomized Clinical Trial.. The journal of contemporary dental practice, 26(2), 119-126. https://doi.org/10.5005/jp-journals-10024-3831
MLA
Ola M Ghoniem, et al.. "Evaluating Lip Repositioning for the Treatment of Excess Gingival Display with and without Pretreatment with Botox: A Randomized Clinical Trial.." The journal of contemporary dental practice, vol. 26, no. 2, 2025, pp. 119-126.
PMID
40444504
Abstract
[OBJECTIVES] To evaluate and compare the treatment of excessive gingival display (EGD) with lip repositioning surgery (LRS), with or without presurgical Botox injection, using relapse as the primary outcome.
[MATERIALS AND METHODS] Twenty-two periodontally healthy patients with EGD were recruited and allocated into two equal groups. The intervention group ( = 11) underwent LRS with Botox preinjection into the smile muscles 1-2 weeks before surgery, while the control group ( = 11) underwent only LRS. Participants were assessed for changes in gingival display and lip length at 3, 6, 9, and 12 months, as well as for pain and satisfaction. The data were recorded and statistically analyzed.
[RESULTS] The control group showed a statistically significant change in gingival display at 3 months (3.82 ± 2.09 mm) and 6 months (4.68 ± 1.72 mm) compared to baseline (5.91 ± 1.45 mm), but no significant changes at 9 months (5.55 ± 1.37 mm) and 12 months (5.64 ± 1.50 mm). The intervention group demonstrated a significant reduction in gingival display at 3 months (2.23 ± 1.29 mm) and 6 months (3.95 ± 1.39 mm), with stable results up to 12 months (4.27 ± 1.10 mm). The overall reduction in gingival display was significantly greater in the intervention group compared to the control group (1.86 mm, 0.27 mm, respectively). Patient satisfaction with the treatment was not significantly different between the two groups, except for willingness to repeat the procedure. Pain scores were significantly higher in the control group than in the Botox group at 24 h, with no significant differences at 3 and 7 days.
[CONCLUSIONS] Botox pre-injection for LRS demonstrated its efficacy for management of EGD by enhancing lip length, reducing relapse, alleviating postoperative discomfort, and providing sustained results for 1 year.
[CLINICAL SIGNIFICANCE] This study addresses effective treatments for EGD, improving esthetics and confidence. By evaluating LRS with and without Botox, it offers practical insights that improves EGD and reduces relapse, resulting in increased patient satisfaction and sustained results over a year. How to cite this article: Ghoniem OM, Madkor GG, Darhous MS. Evaluating Lip Repositioning for the Treatment of Excess Gingival Display with and without Pretreatment with Botox: A Randomized Clinical Trial. J Contemp Dent Pract 2025;26(2):119-126.
[MATERIALS AND METHODS] Twenty-two periodontally healthy patients with EGD were recruited and allocated into two equal groups. The intervention group ( = 11) underwent LRS with Botox preinjection into the smile muscles 1-2 weeks before surgery, while the control group ( = 11) underwent only LRS. Participants were assessed for changes in gingival display and lip length at 3, 6, 9, and 12 months, as well as for pain and satisfaction. The data were recorded and statistically analyzed.
[RESULTS] The control group showed a statistically significant change in gingival display at 3 months (3.82 ± 2.09 mm) and 6 months (4.68 ± 1.72 mm) compared to baseline (5.91 ± 1.45 mm), but no significant changes at 9 months (5.55 ± 1.37 mm) and 12 months (5.64 ± 1.50 mm). The intervention group demonstrated a significant reduction in gingival display at 3 months (2.23 ± 1.29 mm) and 6 months (3.95 ± 1.39 mm), with stable results up to 12 months (4.27 ± 1.10 mm). The overall reduction in gingival display was significantly greater in the intervention group compared to the control group (1.86 mm, 0.27 mm, respectively). Patient satisfaction with the treatment was not significantly different between the two groups, except for willingness to repeat the procedure. Pain scores were significantly higher in the control group than in the Botox group at 24 h, with no significant differences at 3 and 7 days.
[CONCLUSIONS] Botox pre-injection for LRS demonstrated its efficacy for management of EGD by enhancing lip length, reducing relapse, alleviating postoperative discomfort, and providing sustained results for 1 year.
[CLINICAL SIGNIFICANCE] This study addresses effective treatments for EGD, improving esthetics and confidence. By evaluating LRS with and without Botox, it offers practical insights that improves EGD and reduces relapse, resulting in increased patient satisfaction and sustained results over a year. How to cite this article: Ghoniem OM, Madkor GG, Darhous MS. Evaluating Lip Repositioning for the Treatment of Excess Gingival Display with and without Pretreatment with Botox: A Randomized Clinical Trial. J Contemp Dent Pract 2025;26(2):119-126.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botox
|
보툴리눔독소 주사 | dict | 7 | |
| 해부 | lip
|
scispacy | 1 | ||
| 해부 | gingival
|
scispacy | 1 | ||
| 합병증 | Lip
|
scispacy | 1 | ||
| 약물 | Lip
|
C0023759
Lip structure
|
scispacy | 1 | |
| 약물 | EGD
→ excessive gingival display
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS] Botox
|
scispacy | 1 | ||
| 질환 | pain
|
C0030193
Pain
|
scispacy | 1 | |
| 질환 | EGD
→ excessive gingival display
|
scispacy | 1 | ||
| 질환 | Madkor
|
scispacy | 1 | ||
| 기타 | Botox:
|
scispacy | 1 |
MeSH Terms
Humans; Botulinum Toxins, Type A; Lip; Female; Male; Gingiva; Adult; Patient Satisfaction; Smiling; Treatment Outcome; Neuromuscular Agents; Middle Aged
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.